3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6; 2686-86-4 Purity >99.0% Lenalidomide Intermediate Factory
Ruifu Chemical is the leading manufacturer of 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) with high quality, intermediate of Pomalidomide (CAS: 19171-19-8). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Chemical Name | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| Synonyms | 3-Aminopiperidine-2,6-Dione HCl; 3-Amino-2,6-Piperidinedione Hydrochloride; 2,6-Dioxopiperidine-3-Ammonium Chloride |
| CAS Number | 24666-56-6 |
| Related CAS | 2686-86-4; 25181-50-4 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C5H9ClN2O2 |
| Molecular Weight | 164.59 |
| Melting Point | 120℃ |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Off-White Crystalline Powder |
| Purity / Analysis Method | >99.0% (HPLC) |
| Moisture (K.F) | <0.50% |
| Loss on Drying | <0.50% |
| Residue on Ignition | <0.20% |
| Total Impurities | <1.00% |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Lenalidomide (CAS: 191732-72-6) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) is an intermediate for preparing Lenalidomide (CAS: 191732-72-6). Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe. In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
